Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author exact 802002010764 cql: author exact 801000410891

Add to list
- Journal Article
- A1
- open access
A bispecific Clec9A-PD-L1 targeted type I interferon profoundly reshapes the tumor microenvironment towards an antitumor state

Sandra Van Lint (UGent) , Alexander Van Parys (UGent) , Bram Van Den Eeckhout (UGent) , Niels Vandamme (UGent) , Stephane Plaisance, Annick Verhee (UGent) , Dominiek Catteeuw (UGent) , Elke Rogge (UGent) , Jennifer De Geest (UGent) , Nele Vanderroost (UGent) , et al.

(2023) MOLECULAR CANCER. 22(1).
Add to list
- Journal Article
- A1
- open access
Selective IL-1 activity on CD8+ T cells empowers antitumor immunity and synergizes with neovasculature-targeted TNF for full tumor eradication

Bram Van Den Eeckhout (UGent) , Leander Huyghe (UGent) , Sandra Van Lint (UGent) , Elianne Burg (UGent) , Stéphane Plaisance, Frank Peelman (UGent) , Anje Cauwels (UGent) , Gilles Uzé, Niko Kley, Sarah Gerlo (UGent) , et al.

(2021) JOURNAL FOR IMMUNOTHERAPY OF CANCER. 9(11).
Add to list
- Journal Article
- A1
- open access
Targeting IFN activity to both B cells and plasmacytoid dendritic cells induces a robust tolerogenic response and protection against EAE

Anje Cauwels (UGent) , Sandra Van Lint (UGent) , Elke Rogge, Annick Verhee (UGent) , Bram Van Den Eeckhout (UGent) , Shengru Pang, Marco Prinz, Niko Kley, Gilles Uze and Jan Tavernier (UGent)

(2021) SCIENTIFIC REPORTS. 11(1).
Add to list
- Journal Article
- A1
- open access
Specific targeting of IL-1β activity to CD8+ T cells allows for safe use as a vaccine adjuvant

Bram Van Den Eeckhout (UGent) , Lien Van Hoecke (UGent) , Elianne Burg (UGent) , Sandra Van Lint (UGent) , Frank Peelman (UGent) , Niko Kley, Gilles Uzé, Xavier Saelens (UGent) , Jan Tavernier (UGent) and Sarah Gerlo (UGent)

(2020) NPJ VACCINES. 5(1).
Add to list
- Conference Paper
- C3
Selected IL-1 activity on CD8+ T cells allows for safe enhancement of cellular immune responses

Bram Van Den Eeckhout (UGent) , Lien Van Hoecke (UGent) , Elianne Burg (UGent) , Sandra Van Lint (UGent) , Frank Peelman (UGent) , Niko Kley, Gilles Uzé, Xavier Saelens (UGent) , Jan Tavernier (UGent) and Sarah Gerlo (UGent)

(2020) T Cell Memory, Abstracts.
Add to list
- Journal Article
- A1
- open access
Safe eradication of large established tumors using neovasculature-targeted tumor necrosis factor-based therapies

Leander Huyghe (UGent) , Alexander Van Parys (UGent) , Anje Cauwels (UGent) , Sandra Van Lint (UGent) , Stijn De Munter (UGent) , Jennyfer Bultinck (UGent) , Lennart Zabeau (UGent) , Jeroen Hostens, An Goethals, Nele Vanderroost (UGent) , et al.

(2020) EMBO MOLECULAR MEDICINE. 12(2).
Add to list
- Conference Paper
- C3
Towards the use of interleukin-1β as vaccine adjuvant

Bram Van Den Eeckhout (UGent) , Lien Van Hoecke (UGent) , Elianne Burg (UGent) , Sandra Van Lint (UGent) , Frank Peelman (UGent) , Xavier Saelens (UGent) , Jan Tavernier (UGent) and Sarah Gerlo (UGent)

(2019) The 1918 influenza pandemic: historical and biomedical reflections, VIB conference, Abstracts.
Add to list
Targeting interferon activity to dendritic cells enables in vivo tolerization and protection against EAE in mice

Anje Cauwels (UGent) , Sandra Van Lint (UGent) , Dominiek Catteeuw (UGent) , Shengru Pang, Franciane Paul, Elke Rogge (UGent) , Annick Verhee (UGent) , Marco Prinz, Niko Kley, Gilles Uzé, et al.

(2019) JOURNAL OF AUTOIMMUNITY. 97. p.70-76
Add to list
Delivering type I interferon to dendritic cells empowers tumor eradication and immune combination treatments

Anje Cauwels (UGent) , Sandra Van Lint (UGent) , Franciane Paul, Genevieve Garcin, Stefaan De Koker (UGent) , Alexander Van Parys (UGent) , Thomas Wüest (UGent) , Sarah Gerlo (UGent) , José Van Der Heyden (UGent) , Yan Bordat, et al.

(2018) CANCER RESEARCH. 78(2). p.463-474
Add to list
Nanoparticle-conjugate TLR7/8 agonist localized immunotherapy provokes safe antitumoral responses

Lutz Nuhn (UGent) , Stefaan De Koker (UGent) , Sandra Van Lint (UGent) , Zifu Zhong (UGent) , João Portela Catani (UGent) , Francis Combes (UGent) , Kim Deswarte (UGent) , Yupeng Li, Bart Lambrecht (UGent) , Stefan Lienenklaus, et al.

(2018) ADVANCED MATERIALS. 30(45).

Academic Bibliography

A bispecific Clec9A-PD-L1 targeted type I interferon profoundly reshapes the tumor microenvironment towards an antitumor state

Selective IL-1 activity on CD8+ T cells empowers antitumor immunity and synergizes with neovasculature-targeted TNF for full tumor eradication

Targeting IFN activity to both B cells and plasmacytoid dendritic cells induces a robust tolerogenic response and protection against EAE

Specific targeting of IL-1β activity to CD8+ T cells allows for safe use as a vaccine adjuvant

Selected IL-1 activity on CD8+ T cells allows for safe enhancement of cellular immune responses

Safe eradication of large established tumors using neovasculature-targeted tumor necrosis factor-based therapies

Towards the use of interleukin-1β as vaccine adjuvant

Targeting interferon activity to dendritic cells enables in vivo tolerization and protection against EAE in mice

Delivering type I interferon to dendritic cells empowers tumor eradication and immune combination treatments

Nanoparticle-conjugate TLR7/8 agonist localized immunotherapy provokes safe antitumoral responses

Contents

Support

Contact